CN108618150A - 一种护肝降脂胶囊保健品及其制作工艺 - Google Patents
一种护肝降脂胶囊保健品及其制作工艺 Download PDFInfo
- Publication number
- CN108618150A CN108618150A CN201810599230.2A CN201810599230A CN108618150A CN 108618150 A CN108618150 A CN 108618150A CN 201810599230 A CN201810599230 A CN 201810599230A CN 108618150 A CN108618150 A CN 108618150A
- Authority
- CN
- China
- Prior art keywords
- liver
- dropping
- ganoderma lucidum
- poria cocos
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 22
- 230000036541 health Effects 0.000 title claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 33
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 32
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 30
- 210000004185 liver Anatomy 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 244000197580 Poria cocos Species 0.000 claims description 25
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 24
- 235000008599 Poria cocos Nutrition 0.000 claims description 24
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 23
- 235000019441 ethanol Nutrition 0.000 claims description 20
- 150000004676 glycans Chemical class 0.000 claims description 15
- 239000005017 polysaccharide Substances 0.000 claims description 15
- 229920001282 polysaccharide Polymers 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 239000012141 concentrate Substances 0.000 claims description 12
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 11
- 229930182490 saponin Natural products 0.000 claims description 11
- 150000007949 saponins Chemical class 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 10
- 239000000469 ethanolic extract Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 150000003648 triterpenes Chemical class 0.000 claims description 8
- 229930186669 gynosaponin Natural products 0.000 claims description 7
- 239000012535 impurity Substances 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000001766 physiological effect Effects 0.000 claims description 4
- 244000000231 Sesamum indicum Species 0.000 claims description 3
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 241001065361 Gynostemma Species 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 150000002632 lipids Chemical class 0.000 abstract description 7
- 108090000340 Transaminases Proteins 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 102000003929 Transaminases Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 1
- 229930182735 Ganoderic acid Natural products 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种护肝降脂胶囊保健品及其制作工艺，它是由灵芝精粉、茯苓多糖和绞股蓝提取物经加工工艺制作而成。本发明的护肝降脂胶囊具有护肝、降血脂和降转氨酶的优点。
Description
技术领域
本发明涉及保健品领域，具体涉及一种护肝降脂胶囊保健品及其制作工艺。
背景技术
肝脏是人体的重要器官，肝脏具有调节气血，帮助脾胃消化食物、吸收营养、疏理气机及排毒的作用。随着生活节奏的加快，人们摄入的脂肪和酒精含量的增加，增加了肝脏的负担，因此平常生活中，保护肝脏已成为刻不容缓的问题。
灵芝具有滋补强壮、扶正固本的功效，能抗肿瘤、调节免疫、延缓衰老、益气补肝、保肝解毒、降血脂、降血压、降血糖。茯苓能安魂养神、不饥延年，通神而致灵，利窍而益肌，厚肠而开心，调营而理卫。灵芝的功效成分主要是三萜类物质与多糖。茯苓的水溶性多糖（羧甲基茯苓多糖）具有抗肿瘤、调节免疫、抗病毒、降谷-丙转氨酶的功效，还能诱导人血淋巴细胞产生干扰素、白细胞介素、肿瘤坏死因子及粒-巨噬细胞集落刺激因子等天然的抗癌细胞活性因子。绞股蓝被誉为“南方人参”，《救荒本草》称它为神奇的不老长寿药草。绞股蓝具有降血脂、抗肿瘤、抗疲劳、调节免疫、延缓衰老、降血糖、抗溃疡、镇静、催眠等功效。绞股蓝提取物含80%的功效成分---总皂甙，其中有4种绞股蓝皂甙与人参皂甙为同一物质。
《神农本草经》把灵芝Ganoderma lucidum（Leyss. ex Fr.） Karst.、茯苓Poriacocos(Schw.)Wolf列为上品中药，均收载于《中华人民共和国药典》。绞股蓝Gynostemmapentaphyllum (Thunb.) Makino收载于《中药大辞典》，有 “南方人参”之称。把食、药两用真菌灵芝、茯苓与绞股蓝的成分提取出来，制成干粉，按配比混匀，制成护肝降脂胶囊，可以成为一种理想的保健食品。
发明内容
本发明提供了一种护肝降脂胶囊保健品及其制作工艺，该种胶囊具有护肝、降血脂和降转氨酶的优点。
本发明的技术方案如下：
一种护肝降脂胶囊保健品，由以下重量份的材料配制而成：灵芝精粉4～6份、茯苓多糖3～5份、绞股蓝提取物4～6份。
本发明还公开了一种护肝降脂胶囊保健品的制作工艺，包括以下步骤：
（1）选取优质的灵芝、茯苓和绞股蓝；
（2）将灵芝通过挑选、常温清洗除杂、粉碎，然后将灵芝放于热水中浸泡，过滤后制得灵芝提取液，提取液经减压浓缩制成浓缩液，浓缩液再进行喷雾干燥后制得灵芝精粉；
（3）将茯苓粉碎、过目制成茯苓粉，将茯苓粉放入水浸泡、水洗、过滤，将滤液减压浓缩，浓缩液用乙醇醇析分离，制得湿茯苓多糖，湿茯苓多糖经乙醇、乙醚洗涤、干燥、粉碎后制得茯苓水溶性多糖；
（4）将绞股蓝除杂、粉碎、过目后用乙醇浸泡提取，制得乙醇提取液，然后将乙醇提取液蒸馏后获得提取膏，将提取膏干燥、粉碎后制得绞股蓝总皂甙；
（5）将灵芝精粉、茯苓水溶性多糖、绞股蓝总皂甙按配比混匀、装入胶囊制得护肝降脂胶囊。
作为优选的技术方案：所述步骤（5）中的护肝降脂胶囊中，每粒内容物净含量0.25g，含生理活性成份三萜类3.5mg以上，多糖类62.5mg以上，含绞股蓝皂甙62.5mg以上。
作为优选的技术方案：将除杂、粉碎的灵芝放入100℃的热水中浸泡3h，渣再次热水浸提过滤1.5h，两次浸提滤液合并浓缩成8%的浓缩液后进行喷雾干燥。
作为优选的技术方案：所述茯苓粉碎后过80目筛；将茯苓粉放入水中浸泡12h，水洗，过滤，将滤液减压浓缩，后与乙醇的按体积比例1:3进行醇析与分离；所得湿茯苓多糖经乙醇、乙醚洗涤后，先在60℃的环境中干燥10h，然后在105℃的环境中干燥2h，粉碎制得水溶性茯苓多糖粉；
作为优选的技术方案：所述绞股蓝粉碎后过20目筛，将粉碎后的绞股蓝用6倍量的乙醇在70℃的环境中提取2h，将乙醇提取液在80℃的环境中蒸馏，制得提取膏，先将提取膏放在80℃环境中干燥6h，然后在105℃的环境中干燥2h得绞股蓝总皂甙粉。
本发明的优点在于：采用本发明制成的护肝降脂胶囊具有护肝、降血脂和降转氨酶的作用。
具体实施方式
实施例1：
一种护肝降脂胶囊保健品，由以下重量份的材料配制而成：灵芝精粉5份、茯苓多糖4份、绞股蓝提取物5份。
本发明还公开了一种护肝降脂胶囊保健品的制作工艺，包括以下步骤：
（1）选取优质的灵芝、茯苓和绞股蓝。
（2）将灵芝除杂、粉碎，将粉碎的灵芝放入100℃的热水中浸泡3h，渣再次热水浸提过滤1.5h，两次滤液合并、过滤后制取的灵芝提取液，灵芝提取液经浓缩后制成8%的浓缩液，将浓缩液喷雾干燥后制得灵芝精粉。
（3）将茯苓粉碎后过80目筛，将茯苓粉放入水中浸泡12h，水洗，过滤，将滤液减压浓缩，后与95%乙醇按体积比例是1:3进行醇析与分离（浓缩液1V用95%乙醇3V）；所得湿茯苓多糖用乙醇洗涤二次，再用乙醚洗涤一次后先在60℃的环境中干燥10h，然后在105℃的环境中干燥2h，粉碎后制得水溶性茯苓多糖粉。
（4）将绞股蓝除杂、粉碎、过20目筛后用6倍量的乙醇在70℃的环境中提取2h，制得乙醇提取液。将乙醇提取液在80℃的环境中蒸馏，制得提取膏。将提取膏放在80℃环境中干燥6h，然后在105℃的环境中干燥2h，最后粉碎后制得绞股蓝总皂甙粉（含绞股蓝总皂甙80%以上）。
（5）将灵芝精粉、水溶性茯苓多糖粉、绞股蓝总皂甙粉按5-4-5的重量配置混匀、装入胶囊，经刨光、打蜡、包装胶囊和外包装即可制成品。
采用该方案制成的灵芝精粉含水溶性多糖14%，总萜6.4%，总灵芝酸4.2%，总氮5.2%。含三大营养要素：总糖30.8%，粗脂肪5.8%，粗蛋白21.76%。灵芝粉含17种氨基酸，其中7种人体必需氨基酸占氨基酸总量的49.7%-50.7%。灵芝粉含微量元素Zn78.2ppm，Mn120ppm，Sr14.3ppm。
灵芝精粉含活性成份主要为多糖与三萜类，具有保健功能。灵芝精粉口服，可以明显降低因D-安吉半乳糖胺和内毒素合用导致中毒的小鼠血清谷-丙转氨酶活力的升高。灵芝提取物在试管内能减少小鼠原代培养肝细胞受CCl4导致中毒时释放乳酸脱氢酶及谷-丙转氨酶，也可以降低口服CCl4,导致肝中毒血清谷-丙转氨酶，证明灵芝粉对受损的动物肝脏有一定的保护作用。灵芝精粉中的三萜类具有降低血中胆固醇、三甘油酯、ß-脂蛋白的功能，从而能抑制血小板凝结，帮助血液流通，消除血栓，促进血液循环，调节血管压力，增强新陈代谢作用。
茯苓水溶性多糖（羧甲基茯苓多糖）可以使因CCl4导致肝中毒的小鼠血清谷-丙转氨酶下降27.32%-41.03%。绞股蓝总皂甙中有4种绞股蓝皂甙与人参皂甙为同一物质，绞股蓝皂甙具有显著降低血清胆固醇、甘油三酯、低密度脂蛋白的作用。
采用该方案制成的护肝降脂胶囊每粒内容物净含量0.25g，含生理活性成份三萜类3.5mg以上，多糖类62.5mg以上，含绞股蓝皂甙62.5mg以上。成年人每日口服护肝降脂胶囊3次，每次4粒，相当于每日服用三萜类42mg以上，多糖类750mg以上，绞股蓝皂甙750mg以上。在现代基础医学和临床试验证明，灵芝具有滋补强壮、益气安神、健脾活胃、养肝解毒与降血脂等多种功效，对神经衰弱、慢性支气管炎、消化不良、肝炎、白细胞减少症、高血压、高血脂与冠心病心绞痛等疾病有效。茯苓多糖具有免疫调节与保肝降血清谷-丙转氨酶的作用。绞股蓝皂甙具有降血脂的作用。按本方案护肝降脂胶囊产品设计的用法用量，能为肝功异常与高血脂患者提供足够量的生理活性成份三萜、多糖与皂甙类，可以达到保肝、降转氨酶、降血脂的功效。
实施例2：
实施例2与实施例1的区别在于：护肝降脂胶囊是由以下重量份的材料配制而成：灵芝精粉4份、茯苓多糖3份、绞股蓝提取物4份。
实施例3：
实施例3与实施例1的区别在于：护肝降脂胶囊是由以下重量份的材料配制而成：灵芝精粉6份、茯苓多糖5份、绞股蓝提取物6份。
以上所述仅为本发明的优选实施例而已，并不用于限制本发明，对于本领域的技术人员来说，本发明可以有各种更改和变化。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (6)
1.一种护肝降脂胶囊保健品，其特征在于：由以下重量份的材料配制而成：灵芝精粉4～6份、茯苓多糖3～5份、绞股蓝提取物4～6份。
2.如权利要求1所述的护肝降脂胶囊的制作工艺，其特征在于：包括以下步骤：
（1）选取优质的灵芝、茯苓和绞股蓝；
（2）将灵芝通过挑选、常温清洗除杂、粉碎，然后将灵芝放于热水中浸泡，过滤后制得灵芝提取液，提取液经减压浓缩制成浓缩液，浓缩液再进行喷雾干燥后制得灵芝精粉；
（3）将茯苓粉碎、过目制成茯苓粉，将茯苓粉放入水浸泡、水洗、过滤，将滤液减压浓缩，浓缩液用乙醇醇析分离，制得湿茯苓多糖，湿茯苓多糖经乙醇、乙醚洗涤、干燥、粉碎后制得茯苓水溶性多糖；
（4）将绞股蓝除杂、粉碎、过目后用乙醇浸泡提取，制得乙醇提取液，然后将乙醇提取液蒸馏后获得提取膏，将提取膏干燥、粉碎后制得绞股蓝总皂甙；
（5）将灵芝精粉、茯苓水溶性多糖、绞股蓝总皂甙按配比混匀、装入胶囊制得护肝降脂胶囊。
3.如权利要求2所述的护肝降脂胶囊的制作工艺，其特征在于：所述步骤（5）中的护肝降脂胶囊中，每粒内容物净含量0.25g，含生理活性成份三萜类3.5mg以上，多糖类62.5mg以上，含绞股蓝皂甙62.5mg以上。
4.如权利要求2所述的护肝降脂胶囊的制作工艺，其特征在于：将除杂、粉碎的灵芝放入100℃的热水中浸泡3h过滤后制得灵芝提取液，渣再次放入100℃的热水中浸提1.5h，将两次滤液合并减压浓缩至8%的浓缩液后进行喷雾干燥。
5.如权利要求2所述的护肝降脂胶囊的制作工艺，其特征在于：所述茯苓粉碎后过80目筛，将茯苓粉放入水中浸泡12h，水洗，过滤，将滤液减压浓缩后，浓缩液用95%乙醇醇析分离，茯苓多糖浓缩液与乙醇的体积比例是1:3；所述湿茯苓多糖用乙醇洗涤二次，后乙醚洗涤一次，先在60℃的环境中干燥10h，然后在105℃的环境中干燥2h。
6.如权利要求2所述的护肝降脂胶囊的制作工艺，其特征在于：所述绞股蓝粉碎后过20目筛，将粉碎后的绞股蓝用6倍量的乙醇在70℃的环境中浸提2h，将乙醇提取液在80℃的环境中蒸馏，制得提取膏，先将提取膏放在80℃环境中干燥6h，然后在105℃的环境中干燥2h。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810599230.2A CN108618150A (zh) | 2018-06-12 | 2018-06-12 | 一种护肝降脂胶囊保健品及其制作工艺 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810599230.2A CN108618150A (zh) | 2018-06-12 | 2018-06-12 | 一种护肝降脂胶囊保健品及其制作工艺 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108618150A true CN108618150A (zh) | 2018-10-09 |
Family
ID=63691740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810599230.2A Pending CN108618150A (zh) | 2018-06-12 | 2018-06-12 | 一种护肝降脂胶囊保健品及其制作工艺 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108618150A (zh) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056057A (zh) * | 1991-05-26 | 1991-11-13 | 裴留成 | 灵蓝浓缩液的制备方法 |
| CN1098883A (zh) * | 1993-08-20 | 1995-02-22 | 华中农业大学 | 绞股蓝蜂蜜的生产方法及其制品 |
| CN1781530A (zh) * | 2004-12-03 | 2006-06-07 | 陈剑伟 | 一种绛芝益肝胶囊及其制备工艺 |
| CN101810775A (zh) * | 2010-04-15 | 2010-08-25 | 浙江中医药大学附属第二医院 | 一种降糖中药组合物及滴丸 |
| CN102824476A (zh) * | 2011-06-17 | 2012-12-19 | 福建农大菌草技术开发公司 | 克瑞地森保健胶囊制备方法和用途 |
| WO2013170769A1 (zh) * | 2012-05-18 | 2013-11-21 | 北京北大维信生物科技有限公司 | 一种具有调节血脂作用的药物组合物及其用途 |
| CN104644724A (zh) * | 2013-11-21 | 2015-05-27 | 张名静 | 一种绞股蓝总皂苷提取方法 |
| CN105341928A (zh) * | 2015-12-02 | 2016-02-24 | 烟台燕园科玛健康产业有限公司 | 一种降血糖的保健食品 |
| CN107279648A (zh) * | 2017-07-17 | 2017-10-24 | 怀化学院 | 茯苓固态冲调饮料及其制备方法 |
-
2018
- 2018-06-12 CN CN201810599230.2A patent/CN108618150A/zh active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056057A (zh) * | 1991-05-26 | 1991-11-13 | 裴留成 | 灵蓝浓缩液的制备方法 |
| CN1098883A (zh) * | 1993-08-20 | 1995-02-22 | 华中农业大学 | 绞股蓝蜂蜜的生产方法及其制品 |
| CN1781530A (zh) * | 2004-12-03 | 2006-06-07 | 陈剑伟 | 一种绛芝益肝胶囊及其制备工艺 |
| CN100340266C (zh) * | 2004-12-03 | 2007-10-03 | 陈剑伟 | 一种降脂益肝的胶囊及其制备方法 |
| CN101810775A (zh) * | 2010-04-15 | 2010-08-25 | 浙江中医药大学附属第二医院 | 一种降糖中药组合物及滴丸 |
| CN102824476A (zh) * | 2011-06-17 | 2012-12-19 | 福建农大菌草技术开发公司 | 克瑞地森保健胶囊制备方法和用途 |
| WO2013170769A1 (zh) * | 2012-05-18 | 2013-11-21 | 北京北大维信生物科技有限公司 | 一种具有调节血脂作用的药物组合物及其用途 |
| CN104644724A (zh) * | 2013-11-21 | 2015-05-27 | 张名静 | 一种绞股蓝总皂苷提取方法 |
| CN105341928A (zh) * | 2015-12-02 | 2016-02-24 | 烟台燕园科玛健康产业有限公司 | 一种降血糖的保健食品 |
| CN107279648A (zh) * | 2017-07-17 | 2017-10-24 | 怀化学院 | 茯苓固态冲调饮料及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 张晓娟等: "茯苓多糖的提取纯化及应用研究进展", 《时珍国医国药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10111923B2 (en) | Compositions comprising Cyclocarya paliurus extract and preparation method and uses thereof | |
| CN106606529A (zh) | 一种具有辅助降血糖功效的组合物及其制备方法和应用 | |
| CN105395919A (zh) | 一种含有黑木耳提取物、具有降血脂作用的组合物及其制备方法 | |
| CN104640555A (zh) | 用于治疗代谢综合征的新的洋蓟(Cynara Scolymus)、咖啡属(Coffea spp.)和油橄榄(Olea Europaea)的提取物 | |
| JP2016532724A (ja) | エンブリカのオフィシナリスの種子の抽出物の医療用組成物およびその調製方法 | |
| CN108404062A (zh) | 治疗高脂血症的中药组合物及其制备方法和用途 | |
| JP6140789B2 (ja) | コンパウンドｋ成分の強化された紅参濃縮液を含有する非アルコール性脂肪肝症の予防および治療用薬剤学的組成物、並びに健康機能食品 | |
| CN104523742B (zh) | 一种具有护肝和提高免疫作用的多糖组合物及其应用 | |
| CN102846879B (zh) | 一种降血脂的组合物 | |
| CN106177434A (zh) | 一种包含葛根和玉竹的降血糖保健组合物 | |
| CN106581166A (zh) | 一种具有抗疲劳功效的食品、保健品或药物组合物 | |
| CN102283884A (zh) | 一种三七余甘子组合物及用途 | |
| CN106177479A (zh) | 一种包含石斛和玉竹的降血糖保健组合物 | |
| CN108618150A (zh) | 一种护肝降脂胶囊保健品及其制作工艺 | |
| CN103505664A (zh) | 一种含有决明子的降血脂组合物及制备方法 | |
| KR101381507B1 (ko) | 초단파를 이용한 원형 홍삼 및 이의 제조방법 | |
| CN1115159C (zh) | 一种含紫丹参的药物组合物及其制备方法和应用 | |
| CN1460435A (zh) | 用女贞子和蚕蛹制成的护肝功能食品及其制备方法 | |
| JP2009024027A (ja) | 生理活性組成物 | |
| KR20100005920A (ko) | 순무농축물 및 그의 제조방법 | |
| CN109463685A (zh) | 一种木本降血糖组合物的制备方法和保健品 | |
| JP2003212775A (ja) | 生理活性組成物 | |
| CN103505505A (zh) | 一种含有银杏叶的降血脂组合物及制备方法 | |
| KR101451809B1 (ko) | 율무 및 꾸지뽕잎을 유효성분으로 포함하는 대사질환의 예방, 치료 또는 개선용 조성물 | |
| CN107582880A (zh) | 一种具有降血糖作用的竹笋黄酮组合物及其缓释固体饮料 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181009 |